Swiss biotech investor Xlife Sciences AG said on Wednesday its portfolio company Veraxa Biotech AG would list on U.S.

After selling off a portion of its diabetes care business last year, Ypsomed is now fully exiting the diabetes care business ...

BENGALURU] European shares ended slightly higher on Tuesday (Apr 22) on the back of rising financials and post-earnings gains ...

Britain’s economic outlook faced a big setback as the International Monetary Fund delivered its steepest downgrade for any ...

European stocks erased declines, with indexes getting a boost from the recovery in US markets and L’Oreal SA’s ...

Even though the stock is down notably from the peak price it hit last year, it's still doing far better than in the pre-approval days. Competitors are biting at its heels in the weight loss segment, ...

European shares fell on Tuesday, dragged down by heavyweight Novo Nordisk, while US President Donald Trump’s fresh attacks on ...

The stock fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant ...

(Reuters) -European shares fell on Tuesday as heavyweight Novo Nordisk slumped, while U.S. President Donald Trump's vocal ...

Novo Nordisk A/S slumped after a pill from rival Eli Lilly & Co. helped patients shed weight and control blood sugar about as ...

Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results ...

A unique Novo Nordisk legal challenge to the Medicare drug pricing program could have big implications for the pharma ...